Whole-body 18F-FDG PET/CT scan in a patient with Renal Cancer taken from the PETWB-REP dataset. The following English report (translated from original Chinese) is taken verbatim from the public dataset and has not been modified or otherwise checked for accuracy (see the end for citation).

Findings

After fasting and intravenous injection of 18F-FDG, and resting, a whole-body PET/CT scan was performed.
The whole-body scan showed: The brain morphology and structure were normal, with no abnormal density shadows in the brain parenchyma, and no significant abnormalities in FDG uptake.
No widening of the ventricles, sulci, fissures, or cisterns was observed; the ventricles were symmetrical, and there was no midline shift.
The eyeballs were symmetrical, with no significant abnormalities.
Thickening of the ethmoid sinus mucosa was observed bilaterally, but not in the remaining paranasal sinuses, and the sinus walls were intact.
No thickening of the nasopharyngeal wall was observed, and FDG uptake was normal.
The pharyngeal recesses were symmetrical, the Eustachian tube openings were not narrowed, the infratemporal and pterygopalatine fossae were structurally normal, and the bilateral parapharyngeal spaces were clear with no abnormal FDG uptake.
The palatine tonsils showed physiological uptake.
No abnormal density shadows were observed in the bilateral parotid and submandibular glands.
The laryngopharynx morphology and structure were normal.
Thyroid gland is normal in shape and size, with slightly uneven density; FDG uptake is normal.
Right deep cervical lymph node is slightly enlarged, short diameter approximately 0.6cm; FDG uptake is increased, SUVmax=5.1.
Lung markings are clear bilaterally.
A small solid nodule, approximately 0.2cm in diameter, is present in the lateral basal segment of the left lower lobe; FDG uptake is normal.
A patchy area of increased density is seen in the right middle lobe.
A few linear lesions are present in both lungs; FDG uptake is normal.
No pleural thickening is observed bilaterally; no pleural effusion or pneumothorax is present bilaterally.
No significantly enlarged lymph nodes are seen in the bilateral hilar and mediastinal regions.
Cardiac findings are normal.
Some arterial walls show calcification (including coronary arteries).
No abnormal density shadows are seen bilaterally in the breasts; FDG metabolism is normal.
No esophageal dilation, no obvious thickening or mass in the esophageal wall, and no increased FDG uptake.
No obvious abnormalities in liver shape and size, smooth liver margins, no widening of the hepatic fissure, decreased liver density (CT value: 47 HU), and no abnormalities in FDG uptake.
No obvious widening of the main portal vein, and no dilation of intrahepatic or extrahepatic bile ducts.
No abnormalities in gallbladder shape and size, thickened gallbladder wall, and multiple dense shadows within the gallbladder, the largest being approximately 2.5 cm in long diameter; local FDG uptake is normal.
Normal pancreas shape, no obvious abnormal density shadows in the parenchyma, no widening of the main pancreatic duct, and no obvious abnormalities in FDG uptake.
No abnormalities in spleen shape, size, density, or FDG uptake.
An irregular, mixed-density mass in the lower right kidney, with indistinct borders, measures approximately 8.0*8.1*8.7cm.
Calcifications and cystic shadows are visible within the mass.
FDG uptake is unevenly increased (SUVmax = 13.8).
The mass invades the right renal pelvis, calyces, perirenal space, and anterior pararenal space, with involvement of the adjacent peritoneum.
The boundary between the mass and the adjacent ascending colon and lower border of the liver is indistinct.
Small retroperitoneal lymph nodes are visible, the largest with a short diameter of approximately 0.5cm, showing slightly increased FDG uptake (SUVmax = 3.1).
The left kidney is normal in shape and size.
A small cystic lesion, approximately 0.4cm in diameter, is present in the left renal parenchyma.
FDG metabolism is normal.
High-density shadows are seen in the renal pelvis, calyces, ureter, and bladder, with no significant abnormalities in FDG uptake.
Bilateral adrenal gland imaging shows no significant abnormalities.
Stomach distension is poor, with a significant amount of residual contents.
No obvious thickening of the stomach wall was observed, and FDG uptake was not significantly abnormal.
Intestinal distension is poor, with no obvious thickening or mass in the intestinal wall.
FDG uptake is physiological.
Uterus is normal in shape and size, with no abnormal density shadows observed.
FDG uptake is not abnormal.
No obvious abnormalities were observed in the bilateral adnexa.
Muscle uptake is high throughout the body.
Spinal alignment is normal, with osteophyte formation at the margins of some vertebral bodies.
L5/S1 intervertebral disc bulge with pneumoconiosis and degeneration is present.
The relative margins of the L5/S1 vertebral bodies show increased density and roughness.
FDG metabolism in the bone marrow is normal.

Impression

1. Right renal mass with elevated FDG metabolism, suggestive of malignancy, most likely renal cell carcinoma; please correlate with clinicopathology. Reactive hyperplasia of retroperitoneal lymph nodes is possible, but metastasis should be ruled out; follow-up is recommended.

2. Chronic inflammatory micronodules in the left lower lobe. Atelectasis in the right middle lobe, with a few post-inflammatory lesions in both lungs. Calcification of some arterial walls (including coronary arteries).

3. Fatty liver, chronic cholecystitis, gallstones.

4. Residual contrast agent in the urinary tract, small cyst in the left kidney.

5. Degenerative changes in the spine, L5/S1 disc bulge with pneumothorax, L5/S1 endplate inflammation.

6. No obvious abnormalities on cranial scintigraphy. Chronic inflammation of both ethmoid sinuses. Chronic inflammatory lymph nodes in the right deep cervical space.

This case is from PETWB-REP, a curated dataset of whole-body 18F-FDG PET/CT scans and corresponding radiology reports from 490 patients with a broad spectrum of malignancies. The data were retrospectively collected from patients who underwent clinically indicated whole-body 18F-FDG PET/CT scans at the Shanghai Universal Medical Imaging Diagnostic Center between 2021 and 2024.

License: Creative Commons Attribution 4.0 International (CC BY 4.0)

Citation:
Xue, L., Feng, G., Wenbo, Z., Zhang, Y., Li, L., Wang, S., Peng, L., Peng, S., & Gao, X. (2026). PETWB-REP: A Multi-Cancer Whole-Body FDG PET/CT Dataset with Corresponding Radiology Reports [Data set]. Zenodo. https://doi.org/10.5281/zenodo.18670487